ACADIA Pharmaceuticals Inc (ACAD) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Total Revenue Chart for ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc (ACAD) revenue for FY2025 was USD 1.1B, a 11.9% change from FY2024. ACADIA Pharmaceuticals Inc's revenue grew from USD 4.3M in 2000 to USD 1.1B in 2025 (24749.4% over 25 years). Earnings per share grew from USD 0.39 in 2010 to USD -1.34 in 2022 (-441.6%). Revenue compound annual growth rate: 5-year CAGR of 19.4%, 10-year CAGR of 165.7%, 20-year CAGR of 25.8%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.39B
- Implied Share Price
- $19.80
- Enterprise Value
- $3.50B
- Revenue (TTM)
- $1.14B
- EBITDA
- $98.39M
- Profit Margin
- 33.42%
- Trailing P/E
- 8.57
- Forward P/E
- 25.19
- Price/Book (MRQ)
- 3.35
- Price/Sales (TTM)
- 3.00
- EV/EBITDA
- 35.53
- EV/Revenue
- 3.07
- Dividend Yield
- —
- Book Value
- $7.59
- Free Cash Flow (FY2025)
- $105.15M
- Free Cash Flow Yield
- 3.10%
Snapshot as of 20th October 2026 — not point-in-time controlled, may lag the live market by a few days.